Selected Aspects of Drug use in Renal Failure

  • William M. Bennett
  • Lawrence W. Elzinga
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)


The kidney is the major organ involved in the elimination of drugs and their pharmacologically active metabolites. Thus, the frequency and severity of adverse drug reactions are increased in patients with renal insufficiency. Updated recommendations for the use of relevant drugs in patients with varying degrees of renal dysfunction are available (1–3). This paper will review selected aspects of this large subject, emphasizing topics of recent interest and for which new information is available.


Autosomal Dominant Polycystic Kidney Disease Cyst Fluid Antibacterial Efficacy Cyst Infection Subcutaneous Abscess 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W.M. Bennett, G.R. Aronoff, T.A. Golper, G. Morrison, I. Singer, and D.C. Brater, “Drug Prescribing in Renal Failure: Dosing Guidelines for Adults,” American College of Physicians, Philadelphia (1987).Google Scholar
  2. 2.
    W.E. Reed and S. Sabatini, The use of drugs in renal failure. Seminars in Nephrology 6:259–295 (1986).PubMedGoogle Scholar
  3. 3.
    D.C. Brater, “Drug Use in Clinical Medicine,” B.C. Decker, Toronto (1987).Google Scholar
  4. 4.
    R.J. Osborne, S.P. Joel, and M.L. Slevin, Morphine intoxication in renal failure: role of morphine-6-glucuronide, Br Med J 292:1548–1549 (1986).CrossRefGoogle Scholar
  5. 5.
    J. Sawe, and I. Odar-Cederlof, Kinetics of morphine in patients with renal failure, Eur J Clin Pharmacol 32:377–382 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    G.R. Park, M.P. Shelly, A.R. Manara, and K. Quinn, Sedation in intensive care: morphine and renal failure. Intensive Care Med 13:365–366 (1987).PubMedGoogle Scholar
  7. 7.
    D.F. Woolner, D. Winter, T.J. Frendin, E.J. Begg, K.L. Lemn, and G.J. Wright, Renal failure does not impair the metabolism of morphine, Br J Clin Pharmacol 22:55–59 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    P.J. Ratcliffe, J.W. Sear, QMJ, Hand, and R.A. Moore, Morphine transport in the isolated perfused rat kidney, Proc EDTA-ERA 22:1109–1114 (1985).Google Scholar
  9. 9.
    G.L. Chan, G. Matzke, Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opiod analgesics, Drug Intell Clin Pharm 21:773–783 (1937).Google Scholar
  10. 10.
    K Chan, J Tse, F Jennings, and M. Orme, Pharmacokinetics of low dose intravenous pethidine in patients with renal dysfunction, J Clin Pharmacol 27:516–522 (1987).PubMedGoogle Scholar
  11. 11.
    W.M. Bennett, M.N. Hartnett, R. Craven, D.N. Gilbert, and G.A. Porter, Gentamicin concentrations in blood, urine and renal tissue of patients with end-stage renal disease, J Lab Clin Med 30:389–394 (1977).Google Scholar
  12. 12.
    W.M. Bennett and R. Craven, Ampicillin and trimethoprim- sulfamethoxazole treatment of urinary tract infections in patients with severe renal disease, JAMA 236:946–950 (1976).PubMedCrossRefGoogle Scholar
  13. 13.
    C. Langston, D.A. Roberts, G.A. Porter, and W.M. Bennett, Renal phycomycosis, J Urol 109:941–944 (1973).PubMedGoogle Scholar
  14. 14.
    R. Huseman, A. Grady, D. Welling, and J. Grantham, Macropuncture study of polycystic disease in adult human kidneys, Kidney Int 18:375–385 (1980).PubMedCrossRefGoogle Scholar
  15. 15.
    J.J. Grantham, J.L. Geiser, and A.E. Evan, Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 31:1145–1152 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    R.S. Muther and W.M. Bennett, Cyst fluid antibiotic concentrations in polycystic kidney disease: differences between proximal and distal cysts. Kidney Int 20:519–522 (1981).PubMedCrossRefGoogle Scholar
  17. 17.
    L. Elzinga, T. Golper, A.L. Rashad, M.E. Carr, and W.M. Bennett, Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 32:884–888 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    S.J. Schwab, Efficacy of chloramphenicol in refractory cyst infections in autosomal dominant polycystic kidney disease, Am J Kidney Dis 5:258–261 (1985).PubMedGoogle Scholar
  19. 19.
    W.M. Bennett, L. Elzinga, J.P. Pulliam, A.L. Rashad, and J.M. Barry, Cyst fluid antibiotic concentrations in autosomal dominant polycystic kidney disease. Am J Kidney Dis 6:400–404 (1985).PubMedGoogle Scholar
  20. 20.
    S. Schwab, D. Hinthorn, and J.J. Grantham, pH-dependent accumulation of clinamycin in polycystic kidneys. Am J Kidney Pis 3:63–66 (1983).Google Scholar
  21. 21.
    W.M. Bennett, T.A. Golper, and L.W. Elzinga, Fluoroquinolones in patients with polycystic kidney disease, Aust NZ J Med (in press).Google Scholar
  22. 22.
    S.J. Schwab, S.J. Bander, and S. Klahr, Renal infection in autosomal dominant polycystic kidney disease. Am J Med 82:714–718 (1987).PubMedCrossRefGoogle Scholar
  23. 23.
    R. Sweet and W. Keane, Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron 23:237–240 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    G.R. Matzke, R.L. Lucarotti, and H.S. Shapiro, Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 3:11–17 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    W.M. Bennett, G.W. Wood, D.C. Houghton, and D.N. Gilbert, Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 3:292–296 (1986).Google Scholar
  26. 26.
    W.M. Bennett, G.A. Wood, S.J. Kohlhepp, P.W. Kohnen, D.C. Houghton, and D.N. Gilbert, Experimental gentamicin nephrotoxicity can be prevented by polyaspartic acid, Kidnev Int 33:353 (1988).Google Scholar
  27. 27.
    G.A. Wood, D.R. Norton, S.J. Kohlhepp, P.W. Kohnen, W.M. Bennett, G.A. Porter, D.C. Houghton, R.E. Brummett, and D.N. Gilbert, The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess, J Infect Dis (in press).Google Scholar
  28. 28.
    R.W. Bundtzgen, A.U. Gefbër, D.L. Cohen, and W.A. Craig, Postantibiotic suppression of bacterial growth, Rev Infect Pis 3:28–37 (1981).CrossRefGoogle Scholar
  29. 29.
    J. Blaser, B.B. Stone, and S.H. Zinner, Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model, Antimicrob Agents Chemother 27:343–349 (1985).PubMedCrossRefGoogle Scholar
  30. 30.
    J. Kapusnik, C. Hackbarth, H. Chambers, K. Scott, T. Carpenter, and M. Sande, Efficacy of once daily versus intermittent dosing of tobramycin in neutropenic and normal, sedated guinea pigs with experimental Pseudomonas pneumonia [Abstract 548], in: Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., American Society for Microbiology (1985).Google Scholar
  31. 31.
    M. Pechere, k. Letarte, and J-C Pechere, Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia, J Antimicrob Chemother 19:487–491 (1987).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • William M. Bennett
    • 1
  • Lawrence W. Elzinga
    • 1
  1. 1.Division of Nephrology and HypertensionOregon Health Sciences UniversityPortlandUSA

Personalised recommendations